ASCO: Lisocabtagene maraleucel (liso-cel)
Abstract No : 8040
Indication : Non-Hodgkin’s Lymphoma (aggressive)
Intervention : Lisocabtagene maraleucel
Company : Juno Therapeutics, a Bristol-Myers Squibb company
Technology : CAR T Cell therapy
These interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to 3L+ pts as previously reported (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented.
Read More: https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel
ADAURA trial results at ESMO
ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
Renal Cell Carcinoma Highlights- ESMO 2020
The much-awaited late-breaking results of Phase III Checkmate 9ER came out with outstanding outcomes in metastatic 1st line RCC; it evaluated the combination of Cabozantinib/Nivolumab vs. Sunitinib. These impressive results in 651 patients declared that the median PFS has been doubled when compared to Sunitinib, which is 16.6 vs. 8.3m, respectively. The result also evaluated the OS (40% decrease risk of death) & ORR (55.7 vs. 27.1%), with manageable toxicity, efficacy, and tolerability profile with a low rate of treatment-related discontinuations. It was great to hear that the study met both its primary PFS and secondary OS/ORR, demonstrating the superiority of first-line Cabozantinib/Nivolumab vs Sunitinib across key baseline characteristics, including IMDC risk status, tumor PD-L1 expression, and bone metastases.
KEYNOTE 048 Results at ESMO 2020
Abstract No : Abstract #915MO
Indication : Head & Neck Cancer
Intervention : Pembrolizumab + Chemotherapy
Company : Merck & Co.
Technology : PD-1 inhibitor + Chemo
Long-term follow-up confirmed the statistically significant improvement in OS established at the protocol-specified interim and final analyses for pembro vs E in pts with PD-L1 CPS ≥20 and CPS ≥1 and for pembro+C vs E in pts with PD-L1 CPS ≥20 and CPS ≥1, and total pop. Safety was favorable for pembro vs E and comparable for pembro+C vs E
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-048-NCT02358031-esmo-2020
KEYNOTE-177 approves pembrolizumab as SoC and an obvious choice for 1L patients MSI-H/dMMR mCRC
Abstract No : Abstract #396O
Indication : Colorectal Cancer
Intervention : Pembrolizumab
Company : Merck & Co.
Technology : Immune Checkpoint Inhibitor (ICI)
Pembro monotherapy demonstrated clinically meaningful improvements in HRQoL vs SOC chemotherapy in pts with previously untreated MSI-H/dMMR mCRC.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-177-colorectal-cancer
